The insider buying cluster is a modest positive signal but does not change the binary nature of the Phase 3 readout. Traders should monitor for THIO-104 interim data, which is the primary catalyst. The 21.34% insider ownership provides some alignment but does not de-risk the clinical outcome.
Price Chart
Executive Summary
MAIA Biotechnology announced insider purchases totaling ~$325K by a board member and the CEO, signaling management confidence ahead of a pivotal Phase 3 trial (THIO-104) for lead asset ateganosine in third-line NSCLC. The press release also highlighted positive Phase 2 Part C data showing a 90.5% disease control rate. While the insider buying is a positive signal, the company remains a clinical-stage biotech with no approved products or revenue, and the Phase 3 trial outcome is binary.
Key Facts
- Board member Ramiro Guerrero purchased 185,078 shares (~$252K) at avg $1.36 between Aug 20 and Sep 10, 2026.
- CEO Vlad Vitoc purchased 73,000 shares (~$100K) at avg $1.37 on Sep 14, 2026.
- Directors and officers now hold a 21.34% stake in the company.
- Phase 2 THIO-101 Part C data showed a 90.5% disease control rate (DCR) in the efficacy evaluable population.
- Pivotal Phase 3 trial THIO-104 is ongoing, evaluating ateganosine + cemiplimab in third-line NSCLC.
- Company is clinical-stage with no approved products or revenue.
Financial Impact
Insider purchases total approximately $325,284, representing ~0.38% of the $85M market cap.
Risk Factors
- Phase 3 THIO-104 trial may fail to meet endpoints, leading to significant downside.
- No approved products or revenue; company relies on dilutive financing for operations.
- Forward-looking statements about 'high probability of technical success' are not guarantees.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3362049 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | EFFECT | $1.18 | awaiting T+60 | — | $1.11 (+5.93%) |
Oct 6, 2026 20d ago | 8-K | $1.19 | awaiting T+60 | — | $1.11 (−6.72%) |
Sep 25, 2026 4w ago | S-3 | $1.18 | awaiting T+60 | — | $1.11 (+5.93%) |
Sep 16, 2026 5w ago | Press Release | $1.40 | awaiting T+60 | — | $1.11 (−20.71%) |
Sep 15, 2026 5w ago | Press Release | $1.34 | awaiting T+60 | — | $1.11 (−17.16%) |
Sep 15, 2026 5w ago | Insider Cluster | $1.34 | awaiting T+60 | — | $1.11 (−17.16%) |
Jun 3, 2026 20w ago | Press Release | $1.43 $1.38 | ▼ −3.50% | ▼ −6.00% | $1.11 (−22.38%) |
Jun 2, 2026 20w ago | Insider Cluster | $1.35 $1.39 | ▲ +2.96% | ▲ +1.85% | $1.11 (−17.78%) |
May 19, 2026 22w ago | DEFA14A | $1.23 $1.34 | ▲ +8.94% | ▲ +2.65% | $1.11 (−9.76%) |
May 14, 2026 23w ago | 8-K | $1.26 $1.38 | ▲ +9.52% | ▲ +5.01% | $1.11 (−11.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers